Skip to content
lifestyle.celebhomes.net
Author:
Cingulate Inc.
Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
November 13, 2026
Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King
November 10, 2026
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
September 17, 2026
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
August 13, 2026
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
August 11, 2026
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
July 30, 2026
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
July 2, 2026
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
June 16, 2026
Cingulate Receives Complete Response Letter from FDA for CTx-1301
June 2, 2026